Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Sinopharm Group Co. Ltd. (SHTDY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
11.22-0.01 (-0.13%)
At close: 03:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close11.23
Open11.15
Bid0.00 x 0
Ask0.00 x 0
Day's Range11.14 - 11.22
52 Week Range10.05 - 14.65
Volume11,150
Avg. Volume21,401
Market Cap7.019B
Beta (5Y Monthly)0.65
PE Ratio (TTM)6.06
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.59 (5.25%)
Ex-Dividend DateJun 24, 2022
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for SHTDY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • SINOPHARM GROUP CO. LTD. UNSP A
    Analyst Report: MERCK Kommanditgesellschaft auf AktienMerck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (46% of 2021 sales) provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (36%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (18%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
    Rating
    Fair Value
    Economic Moat
    10 days agoMorningstar
View more
  • Reuters

    INSIGHT-Refugees lack COVID shots because drugmakers fear lawsuits - documents

    Tens of millions of migrants may be denied COVID-19 vaccines from a global programme because some major manufacturers are worried about legal risks from harmful side effects, according to officials and internal documents from Gavi, the charity operating the programme, reviewed by Reuters. The legal concerns are an additional hurdle for public health officials tackling the coronavirus – even as officials say unvaccinated people offer an ideal environment for it to mutate into new variants that threaten hard-won immunity around the world. Many COVID-19 vaccine manufacturers have required that countries indemnify them for any adverse events suffered by individuals as a result of the vaccines, the United Nations says.

  • Bloomberg

    China Vaccine Diplomacy Wavers as Nations Seek Western Shots

    (Bloomberg) -- In the early days of the Covid-19 vaccine rollout, Chinese shots saved countless lives. They kick-started inoculation programs across Asia, Latin America and the Middle East, while richer countries hoarded scarce mRNA shots from Pfizer Inc. and Moderna Inc.Most Read from BloombergChristmas at Risk as Supply Chain ‘Disaster’ Only Gets WorseReshaped by Crisis, an ‘Anti-Biennial’ Reimagines ChicagoThis Is What Europe’s Green Future Looks LikeWhy the Gaza Strip May Be the City of the

Advertisement
Advertisement